Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-262-8 | CAS number: 56-23-5
Immunotoxicity
Administrative data
Description of key information
Studies in rodents have shown significant suppression of immune function following exposure to CTC, but only at doses well above those causing liver effects.
Key value for chemical safety assessment
Additional information
From ATSDR toxicological profile (2005):
Studies in rodents have shown significant suppression of immune function following exposure to CTC, but only at doses well above those causing liver effects: “suppression of immune function (reductions in IgM antibody-forming cell activity, T-cell activity, lymphocyte counts, or host resistance to bacteria) has been observed in animals exposed short-term to oral doses of CTC higher than those causing liver effects. Studies in rodents have shown significant suppression of immune function following exposure to CTC. Exposure of female mice to CTC orally at 500 mg/kg/day for 7 consecutive days caused suppression of T-cell-dependent humoral responses to sheep red blood cells. Exposure of rats up to 160 mg/kg/day for 10 days by oral gavage did not alter the primary antibody response to SRBC, natural killer cell activity, or cytotoxic T-lymphocyte responses; also, spleen and thymus weights were comparable to controls. In female mice exposed to daily gavage doses between 50 and 500 mg/kg/day for 14 days (sufficient for hepatotoxicity) the T-cell-dependent humoral response to SRBC was suppressed at ≥ 50 mg/kg/day, serum anti-SRBC IgM titers were reduced at 100 mg/kg/day, and the absolute number and percentage of CD4+CD8- T-cells per spleen was reduced at 500 mg/kg/day.
Justification for classification or non-classification
No classification is proposed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
